Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring

Unlike traditional anticoagulants, the more recently developed agents rivaroxaban, dabigatran and apixaban target specific factors in the coagulation cascade to attenuate thrombosis. Rivaroxaban and apixaban directly inhibit Factor Xa, whereas dabigatran directly inhibits thrombin. All three drugs e...

Descripción completa

Detalles Bibliográficos
Autores principales: Mueck, Wolfgang, Schwers, Stephan, Stampfuss, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3726366/
https://www.ncbi.nlm.nih.gov/pubmed/23809871
http://dx.doi.org/10.1186/1477-9560-11-10

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3726366/
https://www.ncbi.nlm.nih.gov/pubmed/23809871
http://dx.doi.org/10.1186/1477-9560-11-10

Ejemplares similares